Evidence map›Paper›PMID 42282009›Full record

ArticleResearch square2026

Effector Vδ1 γδ T cells mediate anti-tumor immunity and are reprogrammed by imatinib in human gastrointestinal stromal tumor.

Shan Zeng, Jonathan H Sussman, Montana Morris, Yuntian Fu, Juan Esteban Perez, Jiazhen Rong, Katherine Tardy, Hyunjee Kwak, Taylor Hartlein, Shujing Liu and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shan ZengDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Jonathan H SussmanGraduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Montana MorrisDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Yuntian FuDepartment of Statistics and Data Science, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Juan Esteban PerezDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Jiazhen RongDepartment of Statistics and Data Science, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Katherine TardyDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Hyunjee KwakDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Taylor HartleinDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Shujing LiuDepartment of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Kevin DoDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Ferdinando RossiDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Jennifer Q ZhangDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Xiaowei XuDepartment of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Ronald P DeMatteoDepartment of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Funding

Molecular Mechanisms in Gastrointestinal Stromal TumorR01CA102613 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Ronald P. Dematteo · 2004 to 2026
$9.2M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAM AT PENNT32CA251063 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Ronald P. Dematteo · 2020 to 2026
$2.6M
Leveraging innate immunity for GIST therapyF32CA306227 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Montana Morris · 2025 to 2026
$164k
NCI NIH HHS F32 CA306227NCI NIH HHS R01 CA102613NCI NIH HHS T32 CA251063
6 · The paper itself

Abstract

Gamma-delta (γδ) T cells are emerging effectors of anti-tumor immunity, but their relevance to gastrointestinal stromal tumor, the most common human sarcoma, is not defined. Here, we integrate single-cell transcriptomics, immunophenotypic and T cell receptor profiling, and functional assays of circulating and intratumoral γδ T cells across 68 human GIST specimens. Vδ1 cells predominated within tumors, and their abundance correlated with improved outcomes across 3 separate patient cohorts. γδ T cells from untreated tumors were cytotoxic

Indexed as

Gastrointestinal stromal tumorSingle-cell transcriptomicsT cell receptor (TCR) repertoireTumor immunityVδ1 T cellsγδ T cells

Identifiers

PMID42282009
PMCPMC13252525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.